Status:

COMPLETED

Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-64 years

Phase:

PHASE1

Brief Summary

In this study a known investigational medicinal product called semaglutide will be tested in four different tablet versions. In addition to semaglutide, the different tablet versions C, D, E and F con...

Eligibility Criteria

Inclusion

  • Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent.
  • Body mass index between 21.0 kg/m\^2 and 29.9 kg/m\^2 (both inclusive).
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion

  • Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
  • Use of tobacco and nicotine products, defined as any of the below:1) Smoking more than 5 cigarettes or the equivalent per day.2) Not willing to refrain from smoking and use of nicotine substitute products during the inpatient periods.
  • Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
  • History (as declared by participant) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by participant).
  • Presence or history (as declared by participant) of pancreatitis (acute or chronic).

Key Trial Info

Start Date :

September 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 25 2022

Estimated Enrollment :

290 Patients enrolled

Trial Details

Trial ID

NCT04524832

Start Date

September 29 2020

End Date

February 25 2022

Last Update

October 10 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

Berlin, Germany, 14050